Highlights LumiraDx Limited

Equities

LMDXF

KYG5709L1095

Market Closed - OTC Markets Other stock markets 03:57:34 2024-05-31 pm EDT			5-day change	1st Jan Change
0.02 ^USD	-10.31%		-8.68%	-68.20%

May. 24	Roche, LumiraDx Deal Probed by U.K. Competition Watchdog	DJ
May. 20	U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roche, LumiraDx Deal Probed by U.K. Competition Watchdog	May. 24	DJ
Roche to buy part of LumiraDx diagnostics platform for $295 million	Dec. 29	RE
LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche	Dec. 29	DJ
Earnings Flash (LMDX) LUMIRADX Reports Q2 Revenue $21M, vs. Street Est of $21.5M	23-08-24	MT
LumiraDx Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
LumiraDx Limited Signs Commercial Distribution Agreement with Axon Lab AG for the Commercialization of its LumiraDx Platform and Tests	23-07-31	CI
LumiraDx Files 510(k) Application With US FDA for COVID-19 Test	23-06-30	MT
Powell Testimony Eyed Amid Lower Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	23-06-21	MT
LumiraDx Says it Obtained UK Regulatory 'Validation' for Use of Coronavirus Tests	23-06-21	MT
LumiraDx Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
Earnings Flash (LMDX) LUMIRADX Reports Q1 Revenue $22.2M, vs. Street Est of $19.4M	23-05-16	MT
LumiraDx Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-21	CI
LumiraDx Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Earnings Flash (LMDX) LUMIRADX Reports Q4 Revenue $41.1M, vs. Street Est of $43.5M	23-03-21	MT
Lumiradx Receives FDA Emergency Use Authorization and UK CTDA Approval for Its Fast Lab Solutions Multiplex Covid and Influenza Molecular Assay	23-02-06	CI
LumiraDx Gets Noncompliance Notice From Nasdaq	23-02-01	MT
LumiraDx Limited Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK	23-01-31	CI
LumiraDx Limited Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test	22-12-14	CI
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test	22-11-14	CI
Earnings Flash (LMDX) LUMIRADX Posts Q3 Revenue $42.2M, vs. Street Est of $34.8M	22-11-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights LumiraDx Limited

Equities

LMDXF

KYG5709L1095

Highlights

Filters